Report
EUR 13.86 For Business Accounts Only

With a more favourable environment, PHARMANIAGA improves to Slightly Positive

PHARMANIAGA (MY), a company active in the Drug Retailers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date March 11, 2022, the closing price was MYR 0.73 and its potential was estimated at MYR 0.95.
Underlying
Pharmaniaga

Pharmaniaga is an investment holding company. Through its subsidiaries, Co. is engaged in principal manufacturing of generic pharmaceuticals, logistics and distribution, sales and marketing, supply of medical products & services and hospital equipping. As of Dec. 31, 2012, Co. conducted its operations through the following business segments: Logistics and Distribution, which involves distribution of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment; and Manufacturing, which is engaged in the manufacturing of pharmaceutical products.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch